Argenica Therapeutics (ASX:AGN) is a clinical-stage biopharmaceutical company pioneering neuroprotective therapeutics to mitigate brain damage after stroke and other ischemic brain injuries. Their lead candidate, ARG-007, is a synthetic peptide designed to target and modulate key cellular pathways triggered by oxygen deprivation, thereby preserving neuronal viability and limiting tissue loss. ARG-007 has demonstrated potential in preclinical models to reduce infarct size, improve neurological function, and enhance post-stroke recovery. Currently in Phase 2 clinical trials, Argenica aims to translate this therapeutic promise into improved outcomes for stroke patients, a critical unmet medical need affecting millions worldwide.